What do federal funding cuts mean for MS researchers and those living with the disease? Then, should you kiss your dentist ...

Background Benign multiple sclerosis (MS), characterised by minimal disability despite long disease duration, remains poorly understood in terms of its determinants and prognostic implications. While ...

The patent comes months after Immunic Therapeutics announced CALLIPER study results, which tested vidofludimus calcium in ...

"I'm shocked the medicine's regulator has not investigated hundreds of reports of potential harm," Davey said. "How are we supposed to know what's safe if there are no tests?" For patients, reliable ...

Discover how biomarkers like neurofilament light chain and glial fibrillary acidic protein enhance personalized care for ...

Researchers have created an assessment to identify MS patients who have cognitive impairment but few mobility issues, a newly recognized MS subtype.

Nebraska Medicine has become the first medical center in the world to use allogeneic CAR T-cell therapy to treat multiple sclerosis (MS).

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Panelists at the TIME100 Health Leadership Forum discussed how innovations in health tech and approaching primary care differently can help people live well, longer.

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...